Early Detection and Pharmaceutical
Intervention to Reduce Heart Failure
Incidence

ESN Cleer is a precision therapeutics company developing combination Heart Failure diagnostics/treatments, delivering precision personalised medicine.

 

Heart Failure is the no.1 cause of hospitalisation; 10 million people die of Heart Failure annually with 68 million suffering from this debilitating disease. 5-year survival rates post-diagnosis is only 50% with 10-year survival rates as low as 10%. 

Companion Diagnostic Device (CDx)

We are developing precision medicine strategies in the Heart Failure (HF) drug market with diagnostic and therapeutic Companion Diagnostic Device (CDx) assets to identify the types and stages of HF patients who are most likely to benefit from personalised drug intervention.

The CDx assets include detecting the types and stages of HF currently difficult in the conventional clinical systems, with patient subsets identified for corresponding effective drug intervention. We are developing strategies to access specific HF drugs to combine into multiple CDx opportunities.

ESN Cleer CDx.png

Latest News

14 January 2022

 

Today Federal Minister for Health, the Hon Greg Hunt MP, announced funding for two new Research Centres through the MTPConnect Targeted Translation Research Accelerator Scheme and the Medical Research Future Fund (MRFF). The announcement includes a $10 million commitment over four years and more than $20 million in partner contributions for the Australian Stroke and Heart Research Accelerator (ASHRA), led by a collaborative of academic partners including Monash University.

Professor Peter Currie and Associate Professor Mikael Martino will receive more than half a million dollars to investigate the potential of novel cellular therapies and tissue engineering to prevent heart damage following ischemic injury, to reduce scarring and prevent the onset of heart failure.

A collaborative project led by Professor Stephen Nicholls, in conjunction with Melbourne-based industry partner ESN Cleer, will run a clinical trial to test an exciting new saliva-based heart failure diagnostic device on patients.

Monash Univerity - Victorian Heart Institute
MTPConnect